Medtronic Crecimiento futuro

Future controles de criterios 1/6

Medtronic se prevé un crecimiento anual de los beneficios y los ingresos de 10.4% y 4.4% respectivamente. Se prevé que el BPA sea de grow en 11.3% al año. Se prevé que la rentabilidad de los fondos propios sea de 14.1% en 3 años.

Información clave

10.3%

Tasa de crecimiento de los beneficios

11.2%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Medical Equipment	18.2%
Tasa de crecimiento de los ingresos	4.4%
Rentabilidad financiera futura	14.1%
Cobertura de analistas	Good
Última actualización	13 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Previsiones de crecimiento de beneficios e ingresos

XTRA:2M6 - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
4/30/2026	35,269	5,686	6,838	8,702	23
4/30/2025	33,581	5,240	5,927	8,045	30
4/30/2024	32,237	4,554	5,703	7,641	31
1/26/2024	32,320	4,201	4,931	6,470	N/A
10/27/2023	31,958	4,102	4,045	5,570	N/A
7/28/2023	31,558	3,620	4,444	5,831	N/A
4/28/2023	31,227	3,758	4,580	6,039	N/A
1/27/2023	30,771	4,064	4,166	5,636	N/A
10/28/2022	30,806	4,321	4,822	6,290	N/A
7/29/2022	31,070	5,205	5,721	7,137	N/A
4/29/2022	31,686	5,039	5,978	7,346	N/A
1/28/2022	31,785	4,914	5,678	7,034	N/A
10/29/2021	31,798	4,704	5,773	7,162	N/A
7/30/2021	31,597	3,882	5,855	7,254	N/A
4/30/2021	30,117	3,606	4,885	6,240	N/A
1/29/2021	27,926	2,892	4,631	5,945	N/A
10/30/2020	27,868	3,537	4,752	5,996	N/A
7/31/2020	27,927	4,412	4,756	6,002	N/A
4/24/2020	28,913	4,789	6,021	7,234	N/A
1/24/2020	31,062	5,408	6,659	7,871	N/A
10/25/2019	30,891	4,762	6,298	7,519	N/A
7/26/2019	30,666	4,420	5,671	6,815	N/A
4/26/2019	30,557	4,631	5,873	7,007	N/A
1/25/2019	30,555	4,826	4,867	5,958	N/A
10/26/2018	30,378	2,168	4,864	5,905	N/A
7/27/2018	29,947	3,163	4,568	5,649	N/A
4/27/2018	29,953	3,104	3,616	4,684	N/A
1/26/2018	29,725	2,859	4,313	5,419	N/A
10/27/2017	29,639	5,069	N/A	5,502	N/A
7/28/2017	29,934	4,115	N/A	6,067	N/A
4/28/2017	29,710	4,028	N/A	6,880	N/A
1/27/2017	29,361	3,968	N/A	6,433	N/A
10/28/2016	29,012	4,242	N/A	6,145	N/A
7/29/2016	28,725	3,647	N/A	5,952	N/A
4/29/2016	28,833	3,538	N/A	5,218	N/A
1/29/2016	28,435	2,434	N/A	5,804	N/A
10/30/2015	25,819	2,316	N/A	5,774	N/A
7/31/2015	23,127	2,624	N/A	5,408	N/A
4/24/2015	20,261	2,675	N/A	4,902	N/A
1/23/2015	17,410	3,124	N/A	4,318	N/A
10/24/2014	17,255	2,909	N/A	4,163	N/A
7/25/2014	17,083	2,983	N/A	4,286	N/A
4/25/2014	16,893	3,065	N/A	4,959	N/A
1/24/2014	16,879	3,586	N/A	4,901	N/A
10/25/2013	16,743	3,812	N/A	4,735	N/A
7/26/2013	16,644	3,556	N/A	4,593	N/A
4/26/2013	16,569	3,467	N/A	4,942	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. tasa de ahorro: 2M6(10.4% al año) es superior a la tasa de ahorro (0.6%).

Beneficios frente mercado: 2M6Se prevé que los beneficios de la empresa (10.4% al año) crezcan menos que el mercado German (13% al año).

Beneficios de alto crecimiento: 2M6Se prevé que los beneficios de la empresa crezcan, pero no significativamente.

Ingresos vs. Mercado: 2M6(4.4% al año) se prevé que crezca más despacio que el mercado de German (4.8% al año).

Ingresos de alto crecimiento: 2M6Se prevé que los ingresos de la empresa (4.4% al año) crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Futura rentabilidad financiera (ROE): 2M6Se prevé que la Rentabilidad de los fondos propios de la empresa sea baja dentro de 3 años (14.1%).

Descubre empresas en crecimiento

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Medtronic Crecimiento futuro

Future controles de criterios 1/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Medtronic plc Revises Earnings Guidance for the Fiscal Year 2024

Medtronic plc Raises Earnings Guidance for 2024

Medtronic plc Provides Revenue Results for the Second Half of 2023

Recent updates

Medtronic plc Announces New Advancements in Artificial Intelligence for Endoscopic Care by Unveiling ColonPRO

Medtronic plc Announces SMART Trial One-Year Data Demonstrates Medtronic Evolut™ Tavr Platform as Optimal Treatment for Severe Aortic Stenosis in Patients with Small Annulus, Which Is Primarily Women

Now 20% undervalued

Upcoming dividend of US$0.69 per share

Third quarter dividend of US$0.69 announced

Medtronic plc Presents New Clinical and Real-World Data on the MiniMed™ 780G System from Around the World

Medtronic plc Approves Cash Dividend for the Fourth Quarter of Fiscal Year 2024, Payable on April 12, 2024

Now 20% undervalued

Third quarter 2024 earnings released: EPS: US$0.99 (vs US$0.92 in 3Q 2023)

Now 20% undervalued

Medtronic plc to Report Q3, 2025 Results on Feb 18, 2025

Medtronic plc Announces FDA Approval of Its Percept™? RC Deep Brain Stimulation System

Medtronic Diabetes Announces World's First Approval for MiniMed™ 780G System with Simplera Sync™ Disposable, all-in-one sensor

Medtronic plc Announces FDA Approves the PulseSelect Pulsed Field Ablation System for the Treatment of Both Paroxysmal and Persistent Atrial Fibrillation

Upcoming dividend of US$0.69 per share at 3.5% yield

Medtronic Announces Cash Dividend for Third Quarter of Fiscal Year 2024, Payable on January 12, 2024

Second quarter 2024 earnings released: EPS: US$0.68 (vs US$0.32 in 2Q 2023)

Medtronic plc Revises Earnings Guidance for the Fiscal Year 2024

Medtronic plc Announces Four-Year Results from the Evolut Low Risk Trial

Now 20% undervalued after recent price drop

Orchestra BioMed Holdings, Inc Grants FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT™ for the Treatment of Hypertension in Pacemaker Patients

Upcoming dividend of US$0.69 per share at 3.4% yield

Medtronic Issues Statement on the FDA Circulatory Systems Devices Advisory Panel vote for the Symplicity Spyral Renal Denervation System

Medtronic plc Raises Earnings Guidance for 2024

New minor risk - Profit margin trend

First quarter 2024 earnings released: EPS: US$0.59 (vs US$0.70 in 1Q 2023)

Medtronic plc Approves Cash Dividend for the Second Quarter of Fiscal Year 2024, Payable on October 13, 2023

Full year 2023 earnings released: EPS: US$2.83 (vs US$3.75 in FY 2022)

Medtronic plc Appoints Greg Lewis as New Director

Medtronic plc Presents New Data on MiniMed 780G System on Fixed Meal Dosing and Real-World Time in Range Across Wide Range of Users

Upcoming dividend of US$0.69 per share at 3.1% yield

Medtronic plc Appoints Ken Washington as Chief Technology and Innovation Officer

Full year 2023 earnings released: EPS: US$2.83 (vs US$3.75 in FY 2022)

Medtronic plc Approves Cash Dividend for the First Quarter of Fiscal Year 2024, Payable on July 14, 2023

Medtronic plc Announces Medtronic Extravascular ICD Global Clinical Trial Results Reinforce Device Safety and Effectiveness

Medtronic Extravascular ICD Global Clinical Trial Results Reinforce Device Safety and Effectiveness

Shockwave Medical Reportedly Picks Up Takeover Interest from Two Additional Suitors

Shockwave Medical Reportedly Picks Up Takeover Interest from Two Additional Suitors

Upcoming dividend of US$0.68 per share at 3.5% yield

Third quarter 2023 earnings released: EPS: US$0.92 (vs US$1.10 in 3Q 2022)

Medtronic plc to Report Q3, 2024 Results on Feb 20, 2024

Medtronic Linq Insertable Cardiac Monitor Detects 10 Times More Atrial Fibrillation in Ischemic Stroke Patients At Three Years Compared to Standard of Care

Siemens Healthineers, GE Healthcare Studying Potential Deals with Medtronic's Spun Off Units

Medtronic Announces First Patient Enrolled in U.S. Clinical Trial for Hugo™ Robotic-Assisted Surgery System

Upcoming dividend of US$0.68 per share

Medtronic plc Approves Cash Dividend for the Third Quarter of Fiscal Year 2023, Payable on January 13, 2023

Medtronic Completes Enrollment in Pivotal Trial Evaluating First-Of-Its-Kind Pulsed Field Ablation Catheter for Patients with Atrial Fibrillation

Second quarter 2023 earnings released: EPS: US$0.32 (vs US$0.97 in 2Q 2022)

Medtronic plc Provides Revenue Results for the Second Half of 2023

Medtronic's SPYRAL HTN-ON MED Study Demonstrates Meaningful Clinical Benefits Consistent with Other SPYRAL HTN Renal Denervation Trials

Medtronic plc Launches of Medtronic Neurovascular Co-Lab Platform to Accelerate Innovation in Stroke Treatment

dorsaVi Partners with Medtronic to Develop New Technology

Medtronic plc Introduces New Program Called My Insights Exclusively Made for Individuals Using MiniMed™ 770G System

Medtronic plc to Receive FDA Approval for Pacing the Heart's Natural Conduction System

Medtronic plc Receives FDA Clearance for Expanded Indication of LINQ II™ Insertable Cardiac Monitor for Use in Pediatric Patients Ages 2 and Older

Medtronic plc Announces SYMPLICITY HTN-3 Trial Data Show Sustained Long-Term Blood Pressure Reductions with Medtronic Renal Denervation Procedure

Now 20% undervalued

Upcoming dividend of US$0.68 per share

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento